Navigation Links
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Date:11/6/2008

Months Ended September 30, 2008

For the nine months ended September 30, 2008, Micromet recognized total revenues of $21.4 million, compared to $11.4 million for the same period in 2007. Total operating expenses were $41.0 million for the nine months ended September 30, 2008, compared to $30.6 million for the same period in 2007.

Loss from operations for the nine months ended September 30, 2008 was $19.6 million, similar to the $19.2 million dollar loss from operations over the same period in 2007.

For the nine months ended September 30, 2008, Micromet reported a net loss of $27.4 million, or $0.67 per basic and diluted common share, compared to a net loss of $16.3 million, or $0.47 per basic and diluted common share, for the same period in 2007. The net loss for the nine months ending September 30, 2008 includes a non-cash charge of $8.5 million reflecting a change in the fair value of warrants issued in connection with a 2007 PIPE financing, compared to a $1.7 million non-cash gain for this item in the same period of 2007.

Net cash used in operating activities was $8.7 million for the nine months ended September 30, 2008 compared to $11.1 million used in operating activities for the same period in 2007. Micromet's cash and cash equivalents were $15.9 million as of September 30, 2008. The net proceeds of $37.4 million from the PIPE financing were received on October 2, 2008 and are not included in the Company's cash balance as of September 30, 2008.

2008 Outlook:

Micromet will present data at the annual meeting of the American Society for Hematology (ASH) on December 8th and 9th in San Francisco. The Company expects to provide a further update on the currently ongoing phase 1 clinical trial of blinatumomab in patients with non-Hodgkin's lymphoma, and initial results of the currently ongoing phase 2 clinical trial of blinatumomab in patients with acute lymphoblastic leukemia.

Conference Call and Audio Webcast Today, N
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
2. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
3. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. EntreMed Reports Third Quarter 2008 Financial Results
9. CV Therapeutics Reports 2008 Third Quarter Financial Results
10. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
11. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... -- PARIS, September 20, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... a central alternative to petroleum-based energy production. However, current ... yield and is more expensive to mass-produce. In addition, ... on the environment is incomplete, experts say. To ... of solar power, a research team from Rochester Institute ...
... contribution to the accelerated development of new, safe ... in the US and around the world, will ... between Arizona State University and Quintiles ( www.quintiles.com ... is a leader in managing clinical research. ...
Cached Biology Technology:Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 3Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 4Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 5Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 6Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 7Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 8Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 9Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 10Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 11Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 12Research team assesses environmental impact of organic solar cells 2Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Opening up a new door in synthetic biology, a ... produces a continuous supply of tiny lipid spheres that ... membrane. "Cells are essentially small, complex bioreactors enclosed by ... California, Irvine. "Effectively producing vesicles with lipid membranes that ...
... TEMPE, Ariz. Humans are having an effect on Earth,s ... the warming of the planet we are causing. Now you ... are leaving behind. The only question is how large of ... in the current issue of Science (Dec. 16, ...
... one step closer, thanks to a new twist on an ... Illinois researchers, led by professors Jianjun Cheng and Fei Wang, ... segments to cells. The team published its work in the ... these are new materials that could potentially be used for ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: